Palliative care for patients with advanced fibrotic lung disease: A randomised controlled phase II and feasibility trial of a community case conference intervention

Thorax

Volumn 70, Issue 9, 2015, Pages 830-839

  Bajwah, Sabrina ^a,b   Ross, Joy R ^a,c   Wells, Athol U ^c,d   Mohammed, Kabir ^e   Oyebode, Christina ^a   Birring, Surinder S ^b   Patel, Amit S ^b   Koffman, Jonathan ^b   Higginson, Irene J ^b   Riley, Julia ^a,c  

^a ROYAL BROMPTON HOSPITAL   (United Kingdom)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

^d ROYAL BROMPTON AND HAREFIELD NHS FOUNDATION TRUST   (United Kingdom)

^e INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADVANCED FIBROTIC INTERSTITIAL LUNG DISEASE; AGED; ANXIETY; ARTICLE; CAREGIVER; CONTROLLED STUDY; DEPRESSION; DISEASE CONTROL; FEASIBILITY STUDY; FEMALE; HOSPITAL2HOME; HUMAN; INTERSTITIAL LUNG DISEASE; INTERVIEW; LUNG FIBROSIS; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PALLIATIVE CARE OUTCOME SCALE; PALLIATIVE THERAPY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SYMPTOM; ADULT; CLINICAL TRIAL; LUNG DISEASES, INTERSTITIAL; MIDDLE AGED; PROCEDURES; PSYCHOLOGY; PULMONARY FIBROSIS;

ADULT; AGED; CAREGIVERS; FEASIBILITY STUDIES; FEMALE; HUMANS; LUNG DISEASES, INTERSTITIAL; MALE; MIDDLE AGED; PALLIATIVE CARE; PULMONARY FIBROSIS; QUALITY OF LIFE;

EID: 84941282111     PISSN: 00406376     EISSN: 14683296     Source Type: Journal    
DOI: 10.1136/thoraxjnl-2014-206583     Document Type: Article

References (30)

1. Hubbard R, Johnston I, Britton J. Survival in patients with cryptogenic fibrosing alveolitis: a population-based cohort study. Chest 1998;113:396-400.
2. Bajwah S, Higginson IJ, Ross JR, et al. Specialist palliative care is more than drugs: a retrospective study of ILD patients. Lung 2012;190:215-20.
3. Bajwah S, Higginson IJ, Ross JR, et al. The palliative care needs for fibrotic interstitial lung disease: a qualitative study of patients, informal caregivers and health professionals. Palliat Med 2013;27:869-76.
4. Bajwah S, Koffman J, Higginson IJ, et al. 'I wish I knew more ⋯' the end-of-life planning and information needs for end-stage fibrotic interstitial lung disease: views of patients, carers and health professionals. BMJ Support Palliat Care 2013;3:84-90.
5. Health and Social Care Act. London: Department of Health, 2012.
6. Health Do. NHS Future Forum: recommendations to government on NHS modernisation. London: Department of Health, 2011.
7. Brazil K, Bainbridge D, Sussman J, et al. Coordination of palliative cancer care in the community: "unfinished business". Support Care Cancer 2009;17:819-28.
8. Abernethy AP, Currow DC, Hunt R, et al. A pragmatic 2×2×2 factorial cluster randomized controlled trial of educational outreach visiting and case conferencing in palliative care-methodology of the Palliative Care Trial [ISRCTN 81117481]. Contemp Clin Trials 2006;27:83-100.
9. Mitchell GK, Del Mar CB, O'Rourke PK, et al. Do case conferences between general practitioners and specialist palliative care services improve quality of life? A randomised controlled trial (ISRCTN 52269003). Palliat Med 2008;22:904-12.
10. Abernethy AP, Currow DC, Shelby-James T, et al. Delivery strategies to optimize resource utilization and performance status for patients with advanced life-limiting illness: results from the "palliative care trial" [ISRCTN 81117481]. J Pain Symptom Manage 2013;45:488-505.
11. Bajwah S, Ross JR, Peacock JL, et al. Interventions to improve symptoms and quality of life of patients with fibrotic interstitial lung disease: a systematic review of the literature. Thorax 2013;68:867-79.
12. Medical Research Council. Developing and evaluating complex interventions: new guidance, 2008.
13. [No authors listed]. American Thoracic Society. Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. American Thoracic Society (ATS), and the European Respiratory Society (ERS). Am J Respir Crit Care Med 2000;161(2 Pt 1):646-64.
14. Well AU, Hansell DM, Barker R, et al. A simple prognostic staging system for idiopathic fibrosing lung disease. The Fleischner Society Annual Meeting. Cleveland, Ohio, 2010
15. Hearn J, Higginson IJ. Development and validation of a core outcome measure for palliative care: the palliative care outcome scale. Palliative Care Core Audit Project Advisory Group. QualHealth Care 1999;8:219-27.
16. Swigris JJ, Yorke J, Sprunger DB, et al. Assessing dyspnea and its impact on patients with connective tissue disease-related interstitial lung disease. Respir Med 2010;104:1350-5.
17. Patel AS, Siegert RJ, Brignall K, et al. The development and validation of the King's Brief Interstitial Lung Disease (K-BILD) health status questionnaire. Thorax 2012;67:804-10.
18. Swigris JJ, Brown KK, Behr J, et al. The SF-36 and SGRQ: validity and first look at minimum important differences in IPF. Respir Med 2010;104: 296-304.
19. Mahler DA, Wells CK. Evaluation of clinical methods for rating dyspnea. Chest 1988;93:580-6.
20. Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand 1983;67:361-70.
21. Weitzner MA, Jacobsen PB, Wagner H Jr, et al. The Caregiver Quality of Life Index-Cancer (CQOLC) scale: development and validation of an instrument to measure quality of life of the family caregiver of patients with cancer. QualLife Res 1999;8:55-63.
22. Novak M, Guest C. Application of a multidimensional caregiver burden inventory. Gerontologist 1989;29:798-803.
23. Strauss A, Corbin J. Basics of qualitative research: techniques and procedures for developing grounded theory. Thousand Oaks, CA: Sage, 1998.
24. Critchley P, Plach N, Grantham M, et al. Efficacy of haloperidol in the treatment of nausea and vomiting in the palliative patient: a systematic review. J Pain Symptom Manage 2001;22:631-4.
25. Puhan MA, Frey M, Buchi S, et al. The minimal important difference of the hospital anxiety and depression scale in patients with chronic obstructive pulmonary disease. Health Qual Life Outcomes 2008;6:46.
26. Higginson IJ, Bausewein C, Reilly CC, et al. An integrated palliative and respiratory care service for patients with advanced disease and refractory breathlessness: a randomised controlled trial. Lancet Respir Med 2014;2:979-87.
27. Collard HR, Ward AJ, Lanes S, et al. Burden of illness in idiopathic pulmonary fibrosis. J Med Econ 2012;15:829-35.
28. Mitchell G, Cherry M, Kennedy R, et al. General practitioner, specialist providers case conferences in palliative care - Lessons learned from 56 case conferences. Aust Fam Physician 2005;34:389-92.
29. Bradley B, Branley HM, Egan JJ, et al., British Thoracic Society Interstitial Lung Disease Guideline Group, British Thoracic Society Standards of Care Committee; Thoracic Society of Australia; New Zealand Thoracic Society; Irish Thoracic Society. Interstitial lung disease guideline: the British Thoracic Society in collaboration with the Thoracic Society of Australia and New Zealand and the Irish Thoracic Society. Thorax 2008;63(Suppl 5):v1-58.
30. Excellence NIfHaC. Diagnosis and managment of suspected idiopathic pulmonary fibrosis. National Clinical Guideline Centre, 2013.